Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Cost of Revenue (2020 - 2025)

Journey Medical (DERM) has disclosed Cost of Revenue for 6 consecutive years, with $5.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue rose 28.72% year-over-year to $5.8 million, compared with a TTM value of $20.2 million through Sep 2025, up 9.31%, and an annual FY2024 reading of $20.9 million, down 8.8% over the prior year.
  • Cost of Revenue was $5.8 million for Q3 2025 at Journey Medical, up from $4.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $11.2 million in Q3 2021 and bottomed at $2.2 million in Q4 2023.
  • Average Cost of Revenue over 5 years is $6.4 million, with a median of $6.4 million recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 122.49% in 2021, then plummeted 70.87% in 2023.
  • Year by year, Cost of Revenue stood at $9.5 million in 2021, then decreased by 18.97% to $7.7 million in 2022, then tumbled by 70.87% to $2.2 million in 2023, then surged by 108.19% to $4.7 million in 2024, then rose by 22.97% to $5.8 million in 2025.
  • Business Quant data shows Cost of Revenue for DERM at $5.8 million in Q3 2025, $4.9 million in Q2 2025, and $4.8 million in Q1 2025.